- Home
- DALN vs PASG Comparison
DALN vs PASG Comparison
Compare DALN & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DALN
- PASG
- Stock Information
- Founded
- DALN 1954
- PASG 2017
- Country
- DALN United States
- PASG United States
- Employees
- DALN N/A
- PASG N/A
- Industry
- DALN Newspapers/Magazines
- PASG Biotechnology: Pharmaceutical Preparations
- Sector
- DALN Consumer Discretionary
- PASG Health Care
- Exchange
- DALN Nasdaq
- PASG Nasdaq
- Market Cap
- DALN 38.1M
- PASG 31.1M
- IPO Year
- DALN 2008
- PASG 2020
- Fundamental
- Price
- DALN $4.56
- PASG $0.35
- Analyst Decision
- DALN
- PASG Strong Buy
- Analyst Count
- DALN 0
- PASG 3
- Target Price
- DALN N/A
- PASG $7.67
- AVG Volume (30 Days)
- DALN 50.1K
- PASG 180.6K
- Earning Date
- DALN 03-17-2025
- PASG 03-04-2025
- Dividend Yield
- DALN N/A
- PASG N/A
- EPS Growth
- DALN N/A
- PASG N/A
- EPS
- DALN 0.02
- PASG N/A
- Revenue
- DALN $125,391,000.00
- PASG N/A
- Revenue This Year
- DALN N/A
- PASG N/A
- Revenue Next Year
- DALN N/A
- PASG N/A
- P/E Ratio
- DALN $235.00
- PASG N/A
- Revenue Growth
- DALN N/A
- PASG N/A
- 52 Week Low
- DALN $2.98
- PASG $0.33
- 52 Week High
- DALN $7.86
- PASG $1.64
- Technical
- Relative Strength Index (RSI)
- DALN 27.68
- PASG 31.37
- Support Level
- DALN $5.20
- PASG $0.36
- Resistance Level
- DALN $6.31
- PASG $0.54
- Average True Range (ATR)
- DALN 0.49
- PASG 0.05
- MACD
- DALN -0.17
- PASG -0.00
- Stochastic Oscillator
- DALN 4.85
- PASG 11.93
About DALN DallasNews Corporation Series A
DallasNews Corp is a local news and information publishing company in Texas with commercial printing, distribution, and direct mail capabilities, as well as a presence in emerging media and digital marketing.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.